SonoThera raised an oversubscribed $125 million in Series B financing, using the capital to advance ultrasound-mediated delivery genetic medicines into clinical development. The round was led by Vida Ventures with participation from ARK Invest, Bayer’s venture unit Leaps by Bayer, Otsuka Pharmaceutical, UCB Ventures, Otsuka, and multiple strategic and financial backers. The company plans to move its lead Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease programs through clinical timelines and to scale its RIPPLE delivery and PORE payload engineering platforms. SonoThera expects a first DMD clinical trial in 2027.